In addition, a higher number of CD133+ patients exhibited cancer recurrence than CD133- patients (90.9% vs. 64.3%), and CD133 might be associated with transforming growth factor-β (TGF-β)-related EMT alterations. This evidence concerns the gene PROM1 and cancer.